Source link : https://www.newshealth.biz/health-news/semaglutide-cv-benefits-irrespective-of-weight-lost/
VENICE, Italy — Four-year data from the SELECT cardiovascular outcomes trial show that the anti-obesity drug semaglutide (Wegovy) leads to clinically significant and durable weight loss as well as improvements in waist circumference and waist circumference-to-height ratio (CHECK), in patients with preexisting cardiovascular disease (CVD), overweight or obesity, and without diabetes. Participants lost a mean […]
Author : News Health
Publish date : 2024-05-14 17:28:26
Copyright for syndicated content belongs to the linked Source.
Categories